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Background: Transcutaneous bilirubinometry is widely used to predict hyperbilirubinemia by using several devices.
The aim of this study was to compare the predictive ability of BiliCheck vs JM-103 in identifying neonates not at
risk of significant hyperbilirubinemia, putting the data obtained with the two instruments on our transcutaneous
bilirubin nomogram built with the BiliCheck.
Methods: Transcutaneous bilirubin (TcB) measurement was performed when jaundice appeared in newborn babies
and/or just before discharge from the hospital. It was performed at the forehead with the two instruments within
5 minutes by two experienced neonatologists, each one blind to the value obtained by the other. Blood samples
were drawn to obtain total serum bilirubin (TSB) levels soon after TcB measurements.
Results: A total of 627 paired-sample measurements were obtained from 298 newborn babies. Out of the total
population studied, 16 newborn babies (5.4%) showed significant hyperbilirubinemia defined as TSB value >17 mg/dL,
or as need for phototherapy treatment according to the AAP guidelines. TcB measurements showed false negative
results in the first 60 hours of life using both devices. After the 60th hour of life, TcB measurements using both devices
successfully predicted newborn babies not at risk of significant hyperbilirubinemia, being the JM-103 more reliable than
BC because of fewer false positive results.
Conclusions: Our study shows that both BC and JM-103 can exclude subsequent significant hyperbilirubinemia when
the measurements are performed after the 60th hour of life. Nevertheless, the transcutaneous pre-discharge
screening should be considered only as the first step, and it has to be followed by a follow-up through the first
days after discharge.
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Early discharge of healthy late preterm and full term ne-
onates from hospital influenced an increase in hospital
readmission rates due to hyperbilirubinemia, and even
the more serious reappearance of kernicterus [1,2]. Vis-
ual assessment of jaundice and risk factors evaluation
did not give positive results in predicting subsequent
hyperbilirubinemia [3,4], while plotting total serum bili-
rubin (TSB) measurements on hour-specific nomograms
allowed the reduction in hospital readmission rate for
severe hyperbilirubinemia (TSB > 30 mg/dl) [5-8]. The* Correspondence: cromagnoli@rm.unicatt.it
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distribution, and reproduction in any mediumsuitability of transcutaneous determination of bilirubin
(TcB) to reduce both the need and adverse effects of
TSB measurement has been widely documented [9-15].
Several hour-specific nomograms for TcB have been de-
veloped [14,16-20] but few of them have been prospect-
ively validated [21,22]. In the past years we developed a
skin bilirubin nomogram for the first 96 h of life in a
European normal healthy population using BiliCheck™([BC]
Respironics, Marietta, GA – USA) and then validated it in
a prospective, observational multicenter study [18,22]. BC
and JM-103 (Drager Medical Inc, Telford, Pennsylvania)
reliability has been evaluated in two recently published
papers [23,24]. The purpose of this study was to compare
the predictive ability of BiliCheck vs JM-103 in identifying
neonates not at risk of significant hyperbilirubinemia,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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This prospective cohort study was conducted through
January to July 2011 in a single maternity ward. Ethics com-
mittee of the Department of Paeditrics approved the study
and the consent form. Informed consent was obtained from
both parents. The inclusion criteria were gestational age
≥35 weeks (based on ultrasound assessment in the first
trimester, if available or on postmenstrual age otherwise),
absence of congenital malformation and of any disease re-
quiring an admission to the neonatal intensive care unit.
Intramuscular administration of 1 mg vitamin K was the
only drug administered to studied infants. Breast or bottle
feeding every 3 hours was started within one hour of life.
Measurement of TcB and TSB
The measurement of TcB was performed on each baby
either when he/she was visually jaundiced and/or just
before discharge from the hospital. The determination of
TcB was made at the forehead with the two instruments
within 5 minutes, according to manufacturer instruc-
tions. BC was calibrated before each measurement using
a BiliCal™, and each measurement was performed with 5
readings in different points of neonatal forehead. JM-
103 was used on the forehead performing 5 readings
too. Reading locations for both devices were distanced
from the hairline and free of any bruising, nevus, haem-
angioma or other skin anomalies. Each device was used
by one neonatologist unaware of the other one’s results
and of the TSB level. A blood sample (50 μl) for TSB
measurement was obtained by heel stick puncture, soon
after TcB measurement. Capillary tubes were protected
from ambient light and were assayed with direct spec-
trophotometer (Microbilimeter Dual Beam Plus model,
Ginevri, Rome, Italy) after centrifugation. A total of 627
paired-sample measurements were obtained from 298
newborn babies.
Follow-up of studied infants
Newborn babies were never discharged before 72 h of
age, independently from the mode of delivery. All new-
born babies with a pre-discharge TSB value > 75th per-
centile of our nomogram were discharged only after two
consecutive decreasing TSB values, 12 hours apart, mak-
ing us able to identify the peak TSB level. Newborn in-
fants with pre-discharge TSB level between the 50th and
the 75th percentile were discharged and controlled 48 h
later for hyperbilirubinemia using TSB measurement.
Parents of infants with TSB <50th percentile were coun-
seled to return to the hospital within 5 days, or earlier ifthey observed a persistent jaundice. The decision to use
phototherapy was made by the attending neonatologist
according to AAP guidelines [25]. For babies exposed to
phototherapy we considered only pre-treatment mea-
surements. All perinatal data were recorded in a single
database with a selected log of any event occurring dur-
ing the study period.
Outcome
Measurements of TcB were plotted on our percentile-
based hour-specific nomogram separately by two re-
searchers after completion of the study. Significant
hyperbilirubinemia was defined as TSB value >17 mg/dL,
or as need for phototherapy treatment according to the
AAP guidelines. Newborn babies with TcB value below
the 75th percentile that developed subsequent significant
hyperbilirubinemia were defined as false negative results.
Statistical analysis
In our previous experience, BC showed to be 96% sensi-
tive using the 75th percentile of our nomogram [22].
Sample size and power analysis were calculated assum-
ing that JM-103 would be at least 90% sensitive to be
considered equivalent. Calculations derived a sample size
of 564 paired measurements to yield 80% power with
alfa 0.05.
We used the Student’s t-test for continuous predictors
and the Fisher’s test for categorical data. We calculated
the sensitivity, specificity, positive predictive and nega-
tive values plotting TcB data against the 75th percentile
of our TcB nomogram because this percentile resulted
the best predictor in a previous multicenter study
performed on our population. Receiver operating charac-
teristic (ROC) curve analysis was performed with SPSS
software, which was used to assess the predictive ability
of the two studied devices. ROC curves were compared
using the Hanley & McNeil method.
Results
A total of 298 newborn babies (143 males and 155 fe-
males, 279 full term and 19 late preterm) were enrolled
in the study (Table 1). Mean gestational age (±SD) was
38.7 (1.4) weeks (range: 35–42) and mean birth weight
(BW) was 3200 (440) g (range: 1830–4430). The major-
ity of babies were Caucasian (92.3%) and were born after
spontaneous delivery (58.4%). Breast and/or bottle feed-
ing were the prevalent feeding methods, only 34.9% re-
ceived exclusive breastfeeding. Delayed meconium
passage (>24 h of life) was observed in 20 (6.7%) babies,
and only 12 (4.0%) had a weight loss greater than 10%.
Out of the total studied population, 16 newborn babies
(5.4%) were diagnosed as having significant hyper-
bilirubinemia, and 9 (3.0%) received phototherapy. None
of the babies required an exchange transfusion. No cases
Table 1 Baseline characteristics of the study population
Variables Neonates (298)
Gestational age (wks) 38.7 ± 1.4
> 37 279 (93.6)
35 - 36 19 (6.4)




Cesarean section 117 (39.3)
Ventouse 7 (2.3)
Feeding
Exclusive breast feeding 104 (34.9)
Breast + bottle feeding 160 (53.7)
Bottle feeding 34 (11.4)
Delayed meconium passage (>24 hrs) 20 (6.7)
Weight loss >10% 12 (4.0)
Significant hyperbilirubinemia 16 (5.4)
Required phototherapy 9 (3.0)
TSB >17 mg/dL 7 (2.3)
Values expressed as mean ± SD or number (%).
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jaundiced babies. The mean variation coefficient for BC
and JM-103 was 7.4% ± 1% and 6.9% ± 1.2%, respectively.
Table 2 shows the predictive ability of the 75th per-
centile of our TcB nomogram to identify babies with sig-
nificant hyperbilirubinemia using the TcB measurements
obtained by BC and JM-103. TcB measurements using
both the devices showed false negative results in the first
60 hours of life. In this period, BC values were more reli-
able than JM-103 values because of less false negatives,Table 2 Ability of JM-103 and BC measurements below the 75
significant hyperbilirubinemia, for designated time periods
Hours of age TP (n) FN (n) TN (n) FP (n)
JM-103
24 to 48 hours 2 2 124 47
49 to 60 hours 4 1 79 21
61 to 72 hours 5 0 129 37
73 to 96 hours 13 0 117 46
Total 24 3 449 151
Bilicheck
24 to 48 hours 3 1 73 98
49 to 60 hours 4 1 45 55
61 to 72 hours 5 0 82 84
73 to 96 hours 13 0 73 90
Total 25 2 273 327
TP True Positive, FN False Negative, TN True negative, FP False Positive, PPV Positivebut with more false positives. After the 60th hour of life
there were no false negative results for both the devices,
but JM-103 was more reliable because of less false posi-
tive results.
The ROC curve for the 75th percentile of TcB is shown
in Figure 1 where the true positive rate (sensitivity) was
plotted in function of the false positive rate (1-specifi-
city). The area under the ROC curve (AUC) measured
the accuracy of the percentiles in predicting significant
hyperbilirubinemia using JM-103 or BC. AUCs for both
the devices were lower in the first 24–60 hours of life
than between 61–96 hours. JM-103 had higher AUC
than BC between 61–96 hours, and this difference bor-
ders statistical significance (p = 0.074).
In order to calculate the execution times of both pro-
cedures for a subset of 50 newborn babies, a second in-
vestigator clocked times for TcB measurements. Mean
time for one TcB measurement was 41.2 (5.0) sec (range:
38–55 sec) for BC and 19.2 (2.6) sec (range: 16–25 sec)
for JM-103. The longer time for BC was mainly due to
the calibration procedure.
Discussion
Even if healthy term newborns are discharged in many
countries before the 60th hour of life, this burdening
problem is not yet clearly defined [26]. The Expert Com-
mittee for Severe Neonatal Hyperbilirubinemia and
European Society for Pediatric Research and American
Academy of Pediatrics published detailed recommenda-
tions emphasizing the importance of universal, system-
atic assessment of the risk of severe hyperbilirubinemia,
suggesting that a systems-based approach to prevent se-
vere neonatal hyperbilirubinemia should be implemented
at all birthing facilities and coordinated with continuing
ambulatory care [27]. Therefore, the identification ofth percentile of TcB nomogram (ref. [22]) to predict
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
50.0 72.5 4.1 98.4
80.0 79.0 16.0 98.8
100 77.7 11.9 100
100 71.8 22.0 100
88.9 74.8 13.7 99.3
75.0 42.7 3.0 98.6
80.0 45.0 6.8 97.8
100 49.4 5.6 100
100 44.8 12.6 100
92.6 45.5 7.1 99.3
Predictive Value, NPV Negative Predictive Value.
Figure 1 ROC curves during different hours of age: A) 24–60 h; B) 61–96. Full line and dashed line represent the BC and the JM-103
performance, respectively.
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one of the most challenging problems for the neonatolo-
gist. The use of TSB measurement before discharge from
the hospital reduced the number of babies with very high
levels of bilirubin [5-8], but apparently it did not reduce
the incidence of bilirubin-induced neurological damage
[28]. TcB use to avoid TSB measurement, reducing the
pain and risks of this procedure, progressively increased
during the last years [9-15]. We recently validated our TcB
nomogram in a large Italian prospective study, showing
that 100% of sensitivity can be obtained with TcB mea-
surements only after 48 hours of life, using the 75th per-
centile [22]. However, two recent papers from SouthCarolina and Canada raised some concerns because of
false-negative results from pre-discharge TcB screening
[29,30]. Moreover, it is not known if the hour specific TcB
nomogram developed with measurements obtained with
the BC could have the same predictivity when a different
transcutaneous bilirubinometer is used. The present study
was performed for this reason, in order to compare the
predictive ability of BC vs JM-103 using our transcutane-
ous bilirubin nomogram built with the BC.
Our experience showed that 100% sensitivity was
obtained after 60 hours of life for both devices, giving
JM-103 less false positive results. In the first 60 hours
of life there were false negative results with both devices
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positive results. Furthermore, JM-103 was less time con-
suming and less expensive because of the absence of
consuming materials.
Our data ask for caution when TcB measurements and
TcB nomogram are used as predictive tools if an early
(<60 hours) discharge from the hospital is performed.
While our previous experience with BC showed the best
predictive power after 48 hours of life, in this present
work we had one false negative with both the devices be-
tween 48 and 60 hours of life. These false negative re-
sults would have not been identified even if the risk
factors for hyperbilirubinemia suggested by Keren et al.
and by Maisels et al. were applied [3,21]. In fact, both
the infants were white, males, spontaneously delivered at
36 and 37 weeks of gestation, and had a normal clinical
course in the first 72 hours of life. They were breast and
bottle fed and had a normal weight loss (<7%). They
were discharged at 72 hours of life and were controlled
48 hours later reaching their maximum bilirubin level
(17.2 mg/dL) at 85 and 98 hours of life.
This study has some limitations: it is not a population-
based study because the enrolment was based on clinical
practice, it includes a vast majority of Caucasian new-
born babies, and the incidence of significant hyper-
bilirubinemia is low. Their strengths are its robust
design and the high follow-up rate for enrolled newborn
babies. All babies referred to our ambulatory care facility
for clinical evaluation after discharge, and no case of re-
admission for hyperbilirubinemia was noticed.Conclusions
Our study shows that BC and JM-103 can be used for
the TcB measurements to exclude significant hyper-
bilirubinemia after the 60th hour of life. Nevertheless,
our experience suggests that the pre-discharge screening
for hyperbilirubinemia should be considered only as the
first step of a long route that ends only after an accurate
follow-up through the first days after discharge. There-
fore, we agree with Fay et al. [26] when they state that
the follow-up for hyperbilirubinemia should not be dis-
couraged by risk screening practice, without exposing
newborn babies to unnecessary and unjustified risks.
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